(TBPH) Theravance Biopharma - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 836m USD | Total Return: 72.5% in 12m
Avg Turnover: 5.06M
Qual. Beats: 0
Rev. Trend: 93.0%
Qual. Beats: 0
Warnings
Altman Z'' -5.53 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Theravance Biopharma, Inc. is a South San Francisco-based biopharmaceutical company focused on the development and commercialization of specialized respiratory and neurological therapies. Its primary commercial asset is YUPELRI, a nebulized long-acting muscarinic antagonist (LAMA) indicated for chronic obstructive pulmonary disease (COPD), managed through a strategic partnership with Viatris Inc. In the pharmaceutical sector, these collaborative structures are frequently utilized to leverage the larger partners established commercial infrastructure for product distribution.
The companys clinical pipeline is centered on Ampreloxetine, a norepinephrine reuptake inhibitor currently in Phase 3 trials for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy. Developing orphan drug candidates like Ampreloxetine allows companies to target high-unmet-need populations, which often provides pathways for regulatory exclusivity and specialized pricing models. Investors looking for a deeper dive into these clinical milestones can find comprehensive data sets on ValueRay.
Incorporated in 2013, Theravance Biopharma operates within the NASDAQ-listed pharmaceutical industry, maintaining a business model that balances revenue from commercialized respiratory products with the high-risk, high-reward nature of late-stage clinical development. The company remains focused on expanding its footprint within the United States market through both internal development and strategic alliances.
- YUPELRI sales growth and market share expansion drive near-term revenue performance
- Ampreloxetine Phase 3 clinical trial data determines long-term valuation prospects
- Royalty income from Viatris partnership provides essential cash flow stability
- Regulatory approval risks for pipeline candidates influence future earnings potential
- Capital allocation strategies including debt reduction and buybacks impact shareholder value
| Net Income: 114.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.28 > 0.02 and ΔFCF/TA 37.76 > 1.0 |
| NWC/Revenue: 351.5% < 20% (prev 182.0%; Δ 169.5% < -1%) |
| CFO/TA 0.57 > 3% & CFO 268.8m > Net Income 114.5m |
| Net Debt (-247.9m) to EBITDA (7.99m): -31.03 < 3 |
| Current Ratio: 13.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.3m) vs 12m ago 3.16% < -2% |
| Gross Margin: 80.37% > 18% (prev 0.51%; Δ 7.99k% > 0.5%) |
| Asset Turnover: 26.91% > 50% (prev 19.00%; Δ 7.91% > 0%) |
| Interest Coverage Ratio: 2.32 > 6 (EBITDA TTM 7.99m / Interest Expense TTM 1.82m) |
| A: 0.82 (Total Current Assets 417.6m - Total Current Liabilities 31.8m) / Total Assets 472.3m |
| B: -1.83 (Retained Earnings -864.6m / Total Assets 472.3m) |
| C: 0.01 (EBIT TTM 4.23m / Avg Total Assets 407.9m) |
| D: -4.76 (Book Value of Equity -864.6m / Total Liabilities 181.7m) |
| Altman-Z'' = -5.53 = D |
| DSRI: 0.60 (Receivables 15.6m/15.4m, Revenue 109.8m/65.3m) |
| GMI: 0.63 (GM 80.37% / 50.91%) |
| AQI: 0.12 (AQ_t 0.06 / AQ_t-1 0.46) |
| SGI: 1.68 (Revenue 109.8m / 65.3m) |
| TATA: -0.33 (NI 114.5m - CFO 268.8m) / TA 472.3m) |
| Beneish M = -4.05 (Cap -4..+1) = AAA |
As of May 24, 2026, the stock is trading at USD 16.34 with a total of 257,320 shares traded.
Over the past week, the price has changed by +0.92%,
over one month by -1.21%,
over three months by -15.01% and
over the past year by +72.50%.
Theravance Biopharma has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold TBPH.
- StrongBuy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17.2 | 5.3% |
P/E Forward = 7.9491
P/S = 7.6173
P/B = 3.0177
P/EG = -0.05
Revenue TTM = 109.8m USD
EBIT TTM = 4.23m USD
EBITDA TTM = 7.99m USD
Long Term Debt = 62.5m USD (estimated: total debt 73.3m - short term 10.8m)
Short Term Debt = 10.8m USD (from shortTermDebt, last quarter)
Debt = 116.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 42.7m
Net Debt = -247.9m USD (calculated: Debt 116.0m - CCE 363.9m)
Enterprise Value = 588.3m USD (836.2m + Debt 116.0m - CCE 363.9m)
Interest Coverage Ratio = 2.32 (Ebit TTM 4.23m / Interest Expense TTM 1.82m)
EV/FCF = 4.47x (Enterprise Value 588.3m / FCF TTM 131.5m)
FCF Yield = 22.36% (FCF TTM 131.5m / Enterprise Value 588.3m)
FCF Margin = 119.8% (FCF TTM 131.5m / Revenue TTM 109.8m)
Net Margin = 104.3% (Net Income TTM 114.5m / Revenue TTM 109.8m)
Gross Margin = 80.37% ((Revenue TTM 109.8m - Cost of Revenue TTM 21.5m) / Revenue TTM)
Gross Margin QoQ = 91.88% (prev none%)
Tobins Q-Ratio = 1.25 (Enterprise Value 588.3m / Total Assets 472.3m)
Interest Expense / Debt = 1.57% (Interest Expense 1.82m / Debt 116.0m)
Taxrate = 18.07% (23.4m / 129.2m)
NOPAT = 3.46m (EBIT 4.23m * (1 - 18.07%))
Current Ratio = 12.70 (Total Current Assets 417.6m / Total Current Liabilities 32.9m)
Debt / Equity = 0.40 (Debt 116.0m / totalStockholderEquity, last quarter 290.6m)
Debt / EBITDA = -31.03 (Net Debt -247.9m / EBITDA 7.99m)
Debt / FCF = -1.88 (Net Debt -247.9m / FCF TTM 131.5m)
Total Stockholder Equity = 261.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 28.08% (Net Income 114.5m / Total Assets 472.3m)
RoE = 10.17% (Net Income TTM 114.5m / Total Stockholder Equity 1.13b)
RoCE = 0.36% (EBIT 4.23m / Capital Employed (Equity 1.13b + L.T.Debt 62.5m))
RoIC = 0.77% (NOPAT 3.46m / Invested Capital 451.3m)
WACC = 7.93% (E(836.2m)/V(952.2m) * Re(8.85%) + D(116.0m)/V(952.2m) * Rd(1.57%) * (1-Tc(0.18)))
Discount Rate = 8.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.33 | Cagr: 1.66%
[DCF] Terminal Value 75.44% ; FCFF base≈131.5m ; Y1≈132.1m ; Y5≈139.9m
[DCF] Fair Price = 47.02 (EV 2.18b - Net Debt -247.9m = Equity 2.42b / Shares 51.6m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.17 | # QB: 0
Revenue Correlation: 93.00 | Revenue CAGR: 28.88% | SUE: 0.06 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.07 | Chg30d=-69.57% | Revisions=N/A | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.20 | Chg30d=-37.50% | Revisions=N/A | Analysts=1
EPS current Year (2026-12-31): EPS=0.21 | Chg30d=-94.14% | Revisions=N/A | GrowthEPS=+241.8% | GrowthRev=-21.2%
EPS next Year (2027-12-31): EPS=1.25 | Chg30d=-7.38% | Revisions=+43% | GrowthEPS=+497.6% | GrowthRev=+14.8%
[Analyst] Revisions Ratio: +43%